Antimicrobial resistance is recognized as a growing global threat. Infections from resistant bacteria are now too common, and some pathogens have become resistant to multiple types or classes of antibiotics. The loss of effective antibiotics will undermine the ability to fight infectious diseases and manage the infectious complications common in vulnerable patients undergoing chemotherapy for cancer, dialysis for renal failure, and surgery, especially organ transplantation, for which the ability to treat secondary infections is crucial.When first-line and then second-line antibiotic treatment options are limited by resistance, healthcare providers are forced to use antibiotics that may be more toxic to the patient and frequently less effective. Even when alternative treatments exist, research has shown that patients with resistant infections are often much more likely to die, and survivors have significantly longer hospital stays, delayed recuperation, and long-term disability.
LC-600 (Nano-mupirocin), a PEGylated nano-liposomal formulation of mupirocin, enabled for the first time the use of mupirocin by the parenteral route. Mupirocin is an antibiotic currently limited to topical use due to its short elimination half-life. It has a unique mode of action, not shared by other marketed antibiotic and it is active against resistant pathogens including N. gonorrhea (urgent threat according to CDC), methicillin resistant Staph aureus (MRSA) and Strep pneumonia (serious threats according to CDC). Nano-mupirocin showed superior pharmacokinetic profile compared to free mupirocin and demonstrated efficacy in several animal models by the parenteral route.
Nano-mupirocin can be therefore considered as a new parenteral antibiotic.